Find Vedolizumab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Entyvio

Vedolizumab

arrow
CPHI Middle east
Not Confirmed

Brand Name : Entyvio

Japan
arrow
CPHI Middle east
Not Confirmed

Vedolizumab

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2019 Revenue in Millions : 3,085

2018 Revenue in Millions : 2,351

Growth (%) : 31

blank

02

Brand Name : Entyvio

Vedolizumab

arrow
CPHI Middle east
Not Confirmed

Brand Name : Entyvio

Japan
arrow
CPHI Middle east
Not Confirmed

Vedolizumab

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2020 Revenue in Millions : 3,823

2019 Revenue in Millions : 3,148

Growth (%) : 21

blank

03

Brand Name : Entyvio

Vedolizumab

arrow
CPHI Middle east
Not Confirmed

Brand Name : Entyvio

Japan
arrow
CPHI Middle east
Not Confirmed

Vedolizumab

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2021 Revenue in Millions : 4,267

2020 Revenue in Millions : 3,666

Growth (%) : 25

blank

04

Brand Name : Entyvio

Vedolizumab

arrow
CPHI Middle east
Not Confirmed

Brand Name : Entyvio

Japan
arrow
CPHI Middle east
Not Confirmed

Vedolizumab

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2022 Revenue in Millions : 5,199

2021 Revenue in Millions : 4,267

Growth (%) : 22

blank

05

Brand Name : Entyvio

Vedolizumab

arrow
CPHI Middle east
Not Confirmed

Brand Name : Entyvio

Japan
arrow
CPHI Middle east
Not Confirmed

Vedolizumab

Main Therapeutic Indication : Immunology

Currency : USD

2023 Revenue in Millions : 5,280

2022 Revenue in Millions : 5,199

Growth (%) : 15

blank

06

Brand Name : Entyvio

Vedolizumab

arrow
CPHI Middle east
Not Confirmed

Brand Name : Entyvio

Japan
arrow
CPHI Middle east
Not Confirmed

Vedolizumab

Main Therapeutic Indication : Anti-Inflammatory

Currency : USD

2016 Revenue in Millions : 1,167

2015 Revenue in Millions : 784

Growth (%) : 49

blank

07

Brand Name : Entyvio

Vedolizumab

arrow
CPHI Middle east
Not Confirmed

Brand Name : Entyvio

Japan
arrow
CPHI Middle east
Not Confirmed

Vedolizumab

Main Therapeutic Indication : Anti-inflammatory

Currency : USD

2017 Revenue in Millions : 1,823

2016 Revenue in Millions : 1,245

Growth (%) : 46

blank

08

Brand Name : Entyvio

Vedolizumab

arrow
CPHI Middle east
Not Confirmed

Brand Name : Entyvio

Japan
arrow
CPHI Middle east
Not Confirmed

Vedolizumab

Main Therapeutic Indication : Anti-Inflammatory

Currency : USD

2018 Revenue in Millions : 2,276

2017 Revenue in Millions : 1,709

Growth (%) : 33%

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty